REGENERON PHARMACEUTICALS, INC. (REGN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 6B 12B 18B Q4 '09: 379.3M Q1 '10: 407.8M Q2 '10: 433.7M Q3 '10: 422.2M Q4 '10: 459.1M Q1 '11: 467.7M Q2 '11: 459.7M Q3 '11: 456.5M Q4 '11: 445.8M Q1 '12: 565.4M Q2 '12: 762M Q3 '12: 1.1B Q4 '12: 1.4B Q1 '13: 1.6B Q2 '13: 1.7B Q3 '13: 1.9B Q4 '13: 2.1B Q1 '14: 2.3B Q2 '14: 2.5B Q3 '14: 2.6B Q4 '14: 2.8B Q1 '15: 3.1B Q2 '15: 3.4B Q3 '15: 3.8B Q4 '15: 4.1B Q1 '16: 4.4B Q2 '16: 4.6B Q3 '16: 4.7B Q4 '16: 4.9B Q1 '17: 5B Q2 '17: 5.2B Q3 '17: 5.5B Q4 '17: 5.9B Q1 '18: 6.1B Q2 '18: 6.2B Q3 '18: 6.4B Q4 '18: 6.7B Q1 '19: 6.6B Q2 '19: 6.5B Q3 '19: 6.6B Q4 '19: 6.6B Q1 '20: 7B Q2 '20: 7.4B Q3 '20: 7.9B Q4 '20: 8.5B Q1 '21: 9.2B Q2 '21: 12.4B Q3 '21: 13.5B Q4 '21: 16.1B Q1 '22: 16.5B Q2 '22: 14.2B Q3 '22: 13.7B Q4 '22: 12.2B Q1 '23: 12.4B Q2 '23: 12.7B Q3 '23: 13.1B Q4 '23: 13.1B Q1 '24: 13.1B Q2 '24: 13.5B Q3 '24: 13.8B Q4 '24: 14.2B Q1 '25: 14.1B Q2 '25: 14.2B Q3 '25: 14.2B Q4 '25: 14.3B Q1 '26: 14.9B Q2 '26: 15.5B Q3 '10 Q4 '12 Q1 '15 Q2 '17 Q3 '19 Q4 '21 Q1 '24 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-3.5B 0 3.5B 7B 10.5B Q4 '09: -74.1M Q1 '10: -85.8M Q2 '10: -93.3M Q3 '10: -124.1M Q4 '10: -97.5M Q1 '11: -109.6M Q2 '11: -146.2M Q3 '11: -172.5M Q4 '11: -205.2M Q1 '12: -142M Q2 '12: 5.8M Q3 '12: 266.6M Q4 '12: 457.7M Q1 '13: 588.6M Q2 '13: 659.2M Q3 '13: 693.6M Q4 '13: 743M Q1 '14: 781.6M Q2 '14: 851.5M Q3 '14: 803.2M Q4 '14: 823.9M Q1 '15: 915.9M Q2 '15: 1B Q3 '15: 1.2B Q4 '15: 1.3B Q1 '16: 1.3B Q2 '16: 1.2B Q3 '16: 1.2B Q4 '16: 1.3B Q1 '17: 1.4B Q2 '17: 1.7B Q3 '17: 1.9B Q4 '17: 2.1B Q1 '18: 2.2B Q2 '18: 2.3B Q3 '18: 2.4B Q4 '18: 2.5B Q1 '19: 2.4B Q2 '19: 2.1B Q3 '19: 2.3B Q4 '19: 2.2B Q1 '20: 2.4B Q2 '20: 2.8B Q3 '20: 3.1B Q4 '20: 3.6B Q1 '21: 4B Q2 '21: 6.7B Q3 '21: 7.5B Q4 '21: 8.9B Q1 '22: 9.1B Q2 '22: 6.9B Q3 '22: 6.2B Q4 '22: 4.7B Q1 '23: 4.4B Q2 '23: 4.3B Q3 '23: 4.2B Q4 '23: 4B Q1 '24: 3.9B Q2 '24: 3.9B Q3 '24: 4B Q4 '24: 4B Q1 '25: 3.8B Q2 '25: 3.8B Q3 '25: 3.7B Q4 '25: 3.6B Q1 '26: 3.6B Q2 '26: 3.8B Q3 '10 Q4 '12 Q1 '15 Q2 '17 Q3 '19 Q4 '21 Q1 '24 Q2 '26

Net Income TTM

-3B 0 3B 6B 9B Q4 '09: -67.8M Q1 '10: -83M Q2 '10: -93.5M Q3 '10: -126.4M Q4 '10: -104.5M Q1 '11: -117.4M Q2 '11: -154.4M Q3 '11: -182.9M Q4 '11: -221.8M Q1 '12: -166.7M Q2 '12: -27.4M Q3 '12: 226.4M Q4 '12: 750.3M Q1 '13: 837.5M Q2 '13: 848.1M Q3 '13: 798M Q4 '13: 424.4M Q1 '14: 393.8M Q2 '14: 402.8M Q3 '14: 344.8M Q4 '14: 338.1M Q1 '15: 345.8M Q2 '15: 444.1M Q3 '15: 571.2M Q4 '15: 636.1M Q1 '16: 741.4M Q2 '16: 743M Q3 '16: 797.4M Q4 '16: 895.5M Q1 '17: 963.1M Q2 '17: 1.2B Q3 '17: 1.3B Q4 '17: 1.2B Q1 '18: 1.4B Q2 '18: 1.6B Q3 '18: 1.8B Q4 '18: 2.4B Q1 '19: 2.4B Q2 '19: 2.1B Q3 '19: 2.1B Q4 '19: 2.1B Q1 '20: 2.3B Q2 '20: 3B Q3 '20: 3.2B Q4 '20: 3.5B Q1 '21: 4B Q2 '21: 6.2B Q3 '21: 7B Q4 '21: 8.1B Q1 '22: 7.9B Q2 '22: 5.7B Q3 '22: 5.4B Q4 '22: 4.3B Q1 '23: 4.2B Q2 '23: 4.3B Q3 '23: 4B Q4 '23: 4B Q1 '24: 3.9B Q2 '24: 4.3B Q3 '24: 4.7B Q4 '24: 4.4B Q1 '25: 4.5B Q2 '25: 4.5B Q3 '25: 4.6B Q4 '25: 4.5B Q1 '26: 4.4B Q2 '26: 4.3B Q3 '10 Q4 '12 Q1 '15 Q2 '17 Q3 '19 Q4 '21 Q1 '24 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-3B 0 3B 6B 9B Q2 '10: -75.4M Q3 '10: 96M Q4 '10: 99.2M Q1 '11: 98.2M Q2 '11: 76M Q3 '11: -132.2M Q4 '11: -141.7M Q1 '12: -218.1M Q2 '12: -262.5M Q3 '12: -218.1M Q4 '12: -74.6M Q1 '13: 98.7M Q2 '13: 305.2M Q3 '13: 400.1M Q4 '13: 588.6M Q1 '14: 555.9M Q2 '14: 764.1M Q3 '14: 836M Q4 '14: 752.4M Q1 '15: 597.2M Q2 '15: 518.6M Q3 '15: 1.2B Q4 '15: 1.3B Q1 '16: 1.5B Q2 '16: 1.6B Q3 '16: 1.4B Q4 '16: 1.5B Q1 '17: 1.8B Q2 '17: 1.4B Q3 '17: 1.1B Q4 '17: 1.3B Q1 '18: 1.6B Q2 '18: 2B Q3 '18: 2B Q4 '18: 2.2B Q1 '19: 2.5B Q2 '19: 2.3B Q3 '19: 2.4B Q4 '19: 2.4B Q1 '20: 2.2B Q2 '20: 3B Q3 '20: 2.2B Q4 '20: 2.6B Q1 '21: 2.6B Q2 '21: 2.3B Q3 '21: 5.9B Q4 '21: 7.1B Q1 '22: 8.5B Q2 '22: 8.5B Q3 '22: 5.7B Q4 '22: 5B Q1 '23: 4.3B Q2 '23: 4.7B Q3 '23: 5.2B Q4 '23: 4.6B Q1 '24: 4.7B Q2 '24: 4.1B Q3 '24: 4.2B Q4 '24: 4.4B Q1 '25: 4B Q2 '25: 4.7B Q3 '25: 5.1B Q4 '25: 5B Q1 '26: 5B Q2 '26: 4.7B Q3 '10 Q4 '12 Q1 '15 Q2 '17 Q3 '19 Q4 '21 Q1 '24 Q2 '26

Free Cash Flow TTM

-3B 0 3B 6B 9B Q2 '10: -165.3M Q3 '10: 6.2M Q4 '10: -467K Q1 '11: -892K Q2 '11: -15.4M Q3 '11: -210.4M Q4 '11: -198.9M Q1 '12: -264.2M Q2 '12: -306.6M Q3 '12: -263.6M Q4 '12: -124M Q1 '13: 39.2M Q2 '13: 224.1M Q3 '13: 297.5M Q4 '13: 432.3M Q1 '14: 355.9M Q2 '14: 527.8M Q3 '14: 551.5M Q4 '14: 419.4M Q1 '15: 214.8M Q2 '15: -32.8M Q3 '15: 629.4M Q4 '15: 652.8M Q1 '16: 809.6M Q2 '16: 1.1B Q3 '16: 838.1M Q4 '16: 974M Q1 '17: 1.3B Q2 '17: 992.5M Q3 '17: 815.2M Q4 '17: 1B Q1 '18: 1.3B Q2 '18: 1.6B Q3 '18: 1.6B Q4 '18: 1.8B Q1 '19: 2.1B Q2 '19: 1.9B Q3 '19: 2B Q4 '19: 2B Q1 '20: 1.7B Q2 '20: 2.4B Q3 '20: 1.6B Q4 '20: 2B Q1 '21: 2B Q2 '21: 1.7B Q3 '21: 5.4B Q4 '21: 6.5B Q1 '22: 7.9B Q2 '22: 7.9B Q3 '22: 5.1B Q4 '22: 4.4B Q1 '23: 3.7B Q2 '23: 4.2B Q3 '23: 4.6B Q4 '23: 3.9B Q1 '24: 4.1B Q2 '24: 3.3B Q3 '24: 3.4B Q4 '24: 3.7B Q1 '25: 3.1B Q2 '25: 3.9B Q3 '25: 4.2B Q4 '25: 4.1B Q1 '26: 4.1B Q2 '26: 3.8B Q3 '10 Q4 '12 Q1 '15 Q2 '17 Q3 '19 Q4 '21 Q1 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q1 '11: 89.2M Q2 '11: 90.4M Q3 '11: 91M Q1 '12: 107.7M Q2 '12: 110.2M Q3 '12: 115.8M Q1 '13: 109.4M Q2 '13: 111.1M Q3 '13: 116.7M Q1 '14: 112.2M Q2 '14: 113M Q3 '14: 117.4M Q1 '15: 114.5M Q2 '15: 115.3M Q3 '15: 115.9M Q1 '16: 114.2M Q2 '16: 116.2M Q3 '16: 116.5M Q1 '17: 115.1M Q2 '17: 116.1M Q3 '17: 117M Q1 '18: 114.9M Q2 '18: 114.5M Q3 '18: 115.1M Q1 '19: 115.5M Q2 '19: 114.6M Q3 '19: 114.2M Q1 '20: 115.1M Q2 '20: 117.9M Q3 '20: 113.9M Q1 '21: 110.5M Q2 '21: 110.8M Q3 '21: 113.9M Q1 '22: 113.1M Q2 '22: 114M Q3 '22: 112.8M Q1 '23: 114M Q2 '23: 113.9M Q3 '23: 113.4M Q1 '24: 115.1M Q2 '24: 115.4M Q3 '24: 116.2M Q1 '25: 111.2M Q2 '25: 108.6M Q3 '25: 107.2M Q1 '26: 107.7M Q2 '26: 106M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-25.00 0.00 25.00 50.00 75.00 Q4 '10: -1.27 Q1 '11: -1.38 Q2 '11: -1.76 Q3 '11: -2.03 Q4 '11: -2.44 Q1 '12: -1.84 Q2 '12: -0.45 Q3 '12: 1.95 Q4 '12: 6.61 Q1 '13: 7.40 Q2 '13: 7.49 Q3 '13: 7.02 Q4 '13: 3.80 Q1 '14: 3.51 Q2 '14: 3.57 Q3 '14: 3.05 Q4 '14: 2.97 Q1 '15: 3.02 Q2 '15: 3.86 Q3 '15: 4.95 Q4 '15: 5.51 Q1 '16: 6.44 Q2 '16: 6.44 Q3 '16: 6.89 Q4 '16: 7.74 Q1 '17: 8.31 Q2 '17: 9.96 Q3 '17: 11.01 Q4 '17: 10.32 Q1 '18: 12.32 Q2 '18: 13.80 Q3 '18: 15.65 Q4 '18: 21.30 Q1 '19: 21.13 Q2 '19: 17.99 Q3 '19: 18.68 Q4 '19: 18.46 Q1 '20: 19.90 Q2 '20: 25.83 Q3 '20: 27.36 Q4 '20: 30.67 Q1 '21: 35.33 Q2 '21: 55.69 Q3 '21: 62.63 Q4 '21: 72.07 Q1 '22: 70.59 Q2 '22: 50.09 Q3 '22: 47.42 Q4 '22: 38.23 Q1 '23: 36.79 Q2 '23: 37.82 Q3 '23: 35.05 Q4 '23: 34.76 Q1 '24: 33.86 Q2 '24: 37.77 Q3 '24: 40.42 Q4 '24: 38.33 Q1 '25: 39.33 Q2 '25: 39.73 Q3 '25: 41.81 Q4 '25: 41.57 Q1 '26: 41.05 Q2 '26: 40.47 Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.